Expression of UCP2 is associated with sensitivity to platinum‑based chemotherapy for ovarian serous carcinoma.

MLA

Kawanishi, Masaru, et al. “Expression of UCP2 Is Associated with Sensitivity to Platinum‑based Chemotherapy for Ovarian Serous Carcinoma.” Oncology Letters, vol. 15, no. 6, June 2018, pp. 9923–28. EBSCOhost, https://doi.org/10.3892/ol.2018.8598.

APA

Kawanishi, M., Fukuda, T., Shimomura, M., Inoue, Y., Wada, T., Tasaka, R., Yasui, T., & Sumi, T. (2018). Expression of UCP2 is associated with sensitivity to platinum‑based chemotherapy for ovarian serous carcinoma. Oncology Letters, 15(6), 9923–9928. https://doi.org/10.3892/ol.2018.8598

Chicago

Kawanishi, Masaru, Takeshi Fukuda, Masahiro Shimomura, Yuta Inoue, Takuma Wada, Reiko Tasaka, Tomoyo Yasui, and Toshiyuki Sumi. 2018. “Expression of UCP2 Is Associated with Sensitivity to Platinum‑based Chemotherapy for Ovarian Serous Carcinoma.” Oncology Letters 15 (6): 9923–28. doi:10.3892/ol.2018.8598.